CervoMed (NasdaqCM:CRVO) FY Conference Transcript

CervoMed (NasdaqCM:CRVO) FY Conference March 23, 2026 03:00 PM ET Company ParticipantsMatt Winton - CCO and CBOModeratorGood afternoon, everyone. I am Boobalan Pachaiyappan, Managing Director and Senior Biotech Analyst at Roth Capital Partners. With me today is Matt Winton, who is the Chief Commercial Officer and Chief Business Officer of CervoMed. For those who are new to the story, CervoMed is developing oral drugs for neurodegenerative diseases, including dementia with Lewy bodies, ALS, and FTD, and so o ...